[144] Protagonist Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. (PTGX) filed a Form 144 indicating an intended sale of 50,000 common shares through J.P. Morgan Securities on or after 22 Jul 2025. The shares were acquired via six option exercises between Feb 2020 and Mar 2024 and represent roughly 0.08 % of the 61.98 million shares outstanding. The planned transaction carries an aggregate market value of about $2.76 million based on the filing’s reference price. No prior sales were reported in the past three months, and the filer affirmed awareness of no undisclosed material adverse information. While Form 144 only signals intent—not certainty—of sale, it provides investors with advance notice of potential insider liquidity activity.

Positive

• None.

Negative

• Insider intends to sell 50,000 shares (~0.08 % of float) valued at $2.76 M, which can be viewed as a modest bearish signal.

Insights

Securities Analyst

TL;DR: Small insider sale (~0.08 %) worth $2.8 M; modest bearish signal, limited impact.

The filing shows an insider may dispose of 50 k shares obtained via option exercises. Given PTGX’s 62 M share base, dilution or float impact is immaterial. However, insider selling—especially following recent option vesting—can be interpreted as mild profit-taking and may create short-term pressure if liquidity is thin. No information on the seller’s role is disclosed, tempering interpretation. Overall, the notice is routine and does not alter the fundamental outlook.

Corporate Governance Expert

TL;DR: Routine Rule 144 filing; governance implications minimal.

Form 144 compliance demonstrates adherence to SEC disclosure rules for insiders selling restricted stock. Absence of Rule 10b5-1 plan details means timing discretion exists, but the volume is well below the 1 % safe-harbor threshold, so regulatory risk is negligible. Investors should watch subsequent Form 4s to confirm execution but need not infer governance concerns from this standard notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Commom	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	50000	2761000	61981955	07/22/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/05/2020	Option Exercise	Issuer			23989	02/05/2020	Compensation
Common	10/18/2023	Option Exercise	Issuer			6000	10/18/2023	Compensation
Common	03/08/2024	Option Exercise	Issuer			825	03/08/2024	Compensation
Common	09/08/2023	Option Exercise	Issuer			401	09/08/2023	Compensation
Common	02/15/2024	Option Exercise	Issuer			5700	02/15/2024	Compensation
Common	02/26/2024	Option Exercise	Issuer			13085	02/26/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Protagonist Therapeutics (PTGX) file?

A Form 144 notice of proposed sale of restricted securities under Rule 144.

How many PTGX shares are slated for sale?

50,000 common shares are proposed for sale.

What is the estimated market value of the shares?

The filing lists an aggregate value of approximately $2.76 million.

When could the shares be sold?

On or after 22 July 2025, subject to Rule 144 conditions.

What percentage of shares outstanding does the sale represent?

Roughly 0.08 % of PTGX’s 61.98 million shares outstanding.

Were any PTGX shares sold by this insider in the last 3 months?

No. The filing reports "Nothing to Report" for prior 3-month sales.